Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Artcline Gmbh

Other

Teraklin Aktiengessellschaft

Universitat Rostock

Fim Biotech Gmbh

Steffen Mitzner

Jan Stange

Jens Altrichter

Stephanie Koch

Fanny Doss

Emil Reisinger

Sebastian Klammt

Kathleen Selleng

Frank Emmrich

Rainer Dallwig

Dieter G Weiss

Gunter W Gross

Alexandra Gramowski

Jan Loock

Jens Freytag

Wolfgang Ramlow

Anne Breitruck

Antje Schwarz

Dietmar Schiffmann

Claus Kerkhoff

Peggy Bodammer

Antje Lübcke

Gerd Kruger

Gerd Krüger

Jana Sulz

Hans-Joachim Dollmantel

Anne BREITRÜCK

A method for preparing a leukocyte preparation from a leukocyte fraction and a correspondingly prepared or obtainable leukocyte preparation and its use. The methods include: a) sedimenting the leukocyte fraction removing leukocyte supernatant from the sediment, wherein the leukocyte supernatant is collected or remains in a leukocyte container, b) sedimenting the leukocytes in the leukocyte container, c) washing the sediment in the leukocyte container with a saline solution, and d) resuspending the sediment in the leukocyte container in a storage solution.

Method for preparing a leukocyte preparation and leukocyte preparation

A method for determining an amount of functional albumin includes providing a test sample containing a defined amount of albumin of unknown binding capacity and a reference sample containing the same defined amount of albumin having a reference binding capacity, incubating the test and reference samples with a defined amount of at least one albumin-binding marker M under conditions that allow formation of complexes of the at least one albumin-binding marker M and albumin (M:A), removing the complexes, detecting a presence or an amount of unbound marker M in the samples after removal of the complex (M:A) through a first and a second test strips that allow for a determination of an amount of unbound marker M, and determining the amount of functional albumin based on the presence or the amount detected of marker M.

Methods for determining amount of functional albumin

Determining the relative binding capacity of albumin (A), and amount of functional albumin, involves at least two measurement solutions of a test and reference sample. The measurement solutions contain an albumin-binding marker M. The marker in the measurement solution of the test and reference samples exceeds the presumed available albumin binding capacity. The test sample contains a defined amount of albumin of unknown binding capacity. The reference sample contains the same defined amount of albumin having a reference binding capacity. The measurement solutions are incubated under conditions that allow M:A complexes to form. The M:A complexes are removed. The presence or amount of unbound marker M in the solutions is detected after M:A complex removal by a test strip that allows determination of the unbound marker. The relative binding capacity of albumin in the test sample based on the presence or detected amounts of unbound marker is determined.

Methods for determining the relative binding capacity of albumin

A method for preparing a leukocyte preparation from a leukocyte fraction and a correspondingly prepared or obtainable leukocyte preparation and its use. The method includes: a) sedimenting the leukocyte fraction removing leukocyte supernatant from the sediment, wherein the leukocyte supernatant is collected or remains in a leukocyte container, b) sedimenting the leukocytes in the leukocyte container, c) washing the sediment in the leukocyte container with a saline solution, and d) resuspending the sediment in the leukocyte container in a storage solution.

Method for producing a leukocyte preparation

The invention relates to a clay mineral for use as an agent for reducing the concentration of inorganic phosphate in liquids, in particular in bodily fluids or dialysis liquids, in order to treat hyperphosphatemia, in particular in a renal replacement therapy, wherein before use, the clay mineral is thermally treated at a temperature between 400&#xb0; C. and 800&#xb0; C., preferably between 500&#xb0; C. and 700&#xb0; C., in particular preferably at 550&#xb0; C., over a time period of 60 min to 240 min, preferably 90 min to 180 min, in particular preferably 120 min.

Clay mineral for reducing inorganic phosphates, in particular in renal replacement therapy

The present invention relates to a method for treating blood composition disorders and blood function disorders. Said method comprises steps, in which blood or blood plasma of a patient is brought into extracorporeal contact with a second fluid (bioequivalent), wherein said second fluid is blood or modified blood, which comprises at least granulocytes, thrombocytes, and erythrocytes. Furthermore, the invention relates to devices for performing said method and to the use of such a device or blood or modified blood, which comprises granulocytes, thrombocytes, and erythrocytes, for treating blood composition disorders and blood function disorders.

Methods for treating blood composition and function disorders wherein a patient's blood plasma is extracorporeally contacted with donor blood or modified donor blood

The invention relates to a method for the extra-corporeal qualitative and/or quantitative recording of neuro-toxic substances in the blood plasma of an individual. According to said method, a system containing neurones or neuronal networks, which have been cultivated on or applied to a micro-electrode array or a neuro-chip, in addition to a device for measuring the electrical activity of at least one or several of said neurones are provided, the neurones are brought into contact with a prepared sample of plasma and the electrical activity of the neurones is measured. The aim of the invention is to develop and improve said method in such a way that it supplies reliable, reproducible results for the recording of neuro-toxic substances in the blood plasma of an individual, in particular in the case of encephalopathic conditions, such as for example hepatic failure, or of coma conditions of various origins. To achieve this, prior to measurement, the blood plasma of an individual is prepared by being subjected to a filtration method, preferably an ultra-filtration method, whereby an exclusion limit, which causes the most extensive separation possible of the plasma protein from the other dissolved substances is selected, and/or prior to measurement, the blood plasma of an individual is prepared by being subjected to an extraction of liposoluble substances, using a solvent for liposoluble substances, and the ultra-filtrate or the extract containing the liposoluble substances, or both are used in succession or are blended together for the measurement.

Method for the extra-corporeal qualitative and/or quantitative recording of neurotoxic substances in the blood plasma of an individual

A process and set-up of therapeutic immunomodulation is provided for medicine. Many illnesses (i.e. Sepsis) are, among other things, characterized by a disruption of the immune system. In spite of previous therapies using antibiotics, the mortality rate is still very high. The administration of individual cytokins has not yet resulted in any convincing results. The use of cells in an extra-corporal circulation that can adsorb or self-release immunomodulatory effect substances is a completely new type of complex therapeutic approach to such illnesses, which leads to an improvement in the health of the affected patients.

Method for therapeutic immunmodulation of plasma

The present invention provides a process of separating substances bound to a first protein in a first liquid by means of a membrane separating the first liquid from a second liquid, the process comprising the steps of: a) impregnating the membrane by passing along the membrane a solution comprising a first acceptor protein having an acceptor function for the substances to be separated; b) dialyzing the first liquid against the second liquid, the second liquid comprising a second acceptor protein having an acceptor function for the substances to be separated, wherein the membrane separating the first and second liquids contains tunnel-like structures that permit passage of the substances to be separated to the second liquid but exclude passage of the first protein and the second acceptor protein.

Method for the separation of protein-bound substances from a

Growing community of inventors

Rostock, Germany

Steffen Mitzner